Paper30909397
C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas.
Marona P and 5 others. Cells, 2019. Cited by 34 papers, by iCite.
Cite this record
ConductScience Library. C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas. Papers, record 30909397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30909397
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell Differentiation | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Kidney Neoplasms | Major topic |
| Proto-Oncogene Proteins c-met | Major topic |
| Epithelial-Mesenchymal Transition | |
| Humans | |
| Phenotype |
Source PubMed
References92
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20385023 | Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. | Mol Cancer | 2010 | https://conductscience.org/library/papers/20385023 | PubMed |
| 2 | 23233163 | HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells. | Int J Oncol | 2013 | https://conductscience.org/library/papers/23233163 | PubMed |
| 3 | 21102609 | MET signalling: principles and functions in development, organ regeneration and cancer. | Nat Rev Mol Cell Biol | 2010 | https://conductscience.org/library/papers/21102609 | PubMed |
| 4 | 7854453 | Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. | Nature | 1995 | https://conductscience.org/library/papers/7854453 | PubMed |
| 5 | 28259294 | Understanding c-MET signalling in squamous cell carcinoma of the head & neck. | Crit Rev Oncol Hematol | 2017 | https://conductscience.org/library/papers/28259294 | PubMed |
| 6 | 1944272 | C-terminal truncated forms of Met, the hepatocyte growth factor receptor. | Mol Cell Biol | 1991 | https://conductscience.org/library/papers/1944272 | PubMed |
| 7 | 9258068 | C-met proto-oncogene expression in benign and malignant human renal tissues. | J Urol | 1997 | https://conductscience.org/library/papers/9258068 | PubMed |
| 8 | 28237182 | Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib. | Clin Genitourin Cancer | 2017 | https://conductscience.org/library/papers/28237182 | PubMed |
| 9 | 13130303 | Targeting HIF-1 for cancer therapy. | Nat Rev Cancer | 2003 | https://conductscience.org/library/papers/13130303 | PubMed |
| 10 | 21318618 | Development of second-generation VEGFR tyrosine kinase inhibitors: current status. | Curr Oncol Rep | 2011 | https://conductscience.org/library/papers/21318618 | PubMed |
| 11 | 24827131 | A phase I study of cabozantinib (XL184) in patients with renal cell cancer. | Ann Oncol | 2014 | https://conductscience.org/library/papers/24827131 | PubMed |
| 12 | 9140397 | Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. | Nat Genet | 1997 | https://conductscience.org/library/papers/9140397 | PubMed |
| 13 | 15070743 | Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. | Proc Natl Acad Sci U S A | 2004 | https://conductscience.org/library/papers/15070743 | PubMed |
| 14 | 26482279 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/26482279 | PubMed |
| 15 | 18485877 | The epithelial-mesenchymal transition generates cells with properties of stem cells. | Cell | 2008 | https://conductscience.org/library/papers/18485877 | PubMed |
| 16 | 10353251 | The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. | Nature | 1999 | https://conductscience.org/library/papers/10353251 | PubMed |
| 17 | 18676743 | Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/18676743 | PubMed |
| 18 | 25381264 | Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. | Mol Cancer Ther | 2015 | https://conductscience.org/library/papers/25381264 | PubMed |
| 19 | 16585196 | Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. | Cancer Res | 2006 | https://conductscience.org/library/papers/16585196 | PubMed |
| 20 | 8682590 | Overexpression of the met/HGF receptor in renal cell carcinomas. | Int J Cancer | 1996 | https://conductscience.org/library/papers/8682590 | PubMed |
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42645178 | 1D228 Attenuates Sorafenib Resistance in Renal Cell Carcinoma Models by Dual Targeting c-Met and AXL. | Cells | 2026 | https://conductscience.org/library/papers/42645178 | PubMed |
| 42524595 | Nuclear Mechanotransduction at the Crossroads: How Membrane Receptors Remodel the Perinuclear Cytoskeleton to Drive Cancer and Disease. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42524595 | PubMed |
| 41463290 | Biomimetic Salivary Gland Cancer Spheroid Platform for In Vitro Recapitulation of Three-Dimensional Tumor-Stromal Interactions. | Biomolecules | 2025 | https://conductscience.org/library/papers/41463290 | PubMed |
| 40558302 | Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance. | Curr Oncol | 2025 | https://conductscience.org/library/papers/40558302 | PubMed |
| 39815326 | The endonuclease activity of MCPIP1 controls the neoplastic transformation of epithelial cells via the c-Met/CD44 axis. | Cell Commun Signal | 2025 | https://conductscience.org/library/papers/39815326 | PubMed |
| 39720556 | Recent advances in the treatment of non-small cell lung cancer with MET inhibitors. | Front Chem | 2024 | https://conductscience.org/library/papers/39720556 | PubMed |
| 39365364 | Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy. | Clin Transl Oncol | 2025 | https://conductscience.org/library/papers/39365364 | PubMed |
| 39356364 | Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors. | Mol Divers | 2025 | https://conductscience.org/library/papers/39356364 | PubMed |
| 39092291 | Renal cancer: signaling pathways and advances in targeted therapies. | MedComm (2020) | 2024 | https://conductscience.org/library/papers/39092291 | PubMed |
| 38693863 | Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma. | J Cell Mol Med | 2024 | https://conductscience.org/library/papers/38693863 | PubMed |
| 38687678 | Loss of tumor suppressor TMEM127 drives RET-mediated transformation through disrupted membrane dynamics. | Elife | 2024 | https://conductscience.org/library/papers/38687678 | PubMed |
| 38379085 | Downregulation of praja2 restrains endocytosis and boosts tyrosine kinase receptors in kidney cancer. | Commun Biol | 2024 | https://conductscience.org/library/papers/38379085 | PubMed |
| 38239394 | Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma. | Cancer Drug Resist | 2023 | https://conductscience.org/library/papers/38239394 | PubMed |
| 36982721 | An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36982721 | PubMed |
| 36839989 | Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/36839989 | PubMed |
| 36421797 | Tumorigenesis Mechanisms Found in Hereditary Renal Cell Carcinoma: A Review. | Genes (Basel) | 2022 | https://conductscience.org/library/papers/36421797 | PubMed |
| 35582583 | Dodging the bullet: therapeutic resistance mechanisms in pediatric cancers. | Cancer Drug Resist | 2019 | https://conductscience.org/library/papers/35582583 | PubMed |
| 35205843 | c-Met and EPHA7 Receptor Tyrosine Kinases Are Related to Prognosis in Clear Cell Renal Cell Carcinoma: Focusing on the Association with Myoferlin Expression. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35205843 | PubMed |
| 35122106 | c-Met up-regulates the expression of PD-L1 through MAPK/NF-κBp65 pathway. | J Mol Med (Berl) | 2022 | https://conductscience.org/library/papers/35122106 | PubMed |
| 34681854 | LncRNAs in the Regulation of Genes and Signaling Pathways through miRNA-Mediated and Other Mechanisms in Clear Cell Renal Cell Carcinoma. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34681854 | PubMed |
Genes32
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30909397
GET https://conductscience.org/api/papers/v1/30909397/references?page=2